-
Despite Headwinds, Cowen Sees TripAdvisor Traveling Higher Long-Term
Wednesday, June 15, 2016 - 11:25am | 294Read More...Cowen’s Kevin Kopelman believes the Street is underestimating the pressure on Tripadvisor Inc (NASDAQ: TRIP) during FY16, as well as the potential for a rebound in FY17. Kopelman maintains a Market Perform rating on the company, while raising the price target from $65 to $70. Favorable Setup...
-
Cowen Says Ocular Therapeutix's OTX-DP Miss 'Meaningless' To Bull Thesis
Monday, June 6, 2016 - 2:36pm | 242Read More...Shares of Ocular Therapeutix Inc (NASDAQ: OCUL) were trading down more than 42 percent on Monday, after the company announced its second Phase 3 clinical trial evaluating its lead product candidate DEXTENZA (sustained release dexamethasone) for the treatment of ocular itching associated with...
-
Natera Shares Down 12%; Cowen Reiterated Outperform Following Meetings With Management
Wednesday, June 1, 2016 - 4:37pm | 249Read More...Natera Inc (NASDAQ: NTRA) reported its first quarter financial results on Tuesday. The net loss reached ($0.17) per share and revenue came in at $61.9 million. The stock fell 12.11 percent on Wednesday. Cowen recently hosted a few investor meetings with Natera’s Senior Management team....
-
Cowen: JetBlue Can Overcome April Revenue 'Blues'
Wednesday, April 27, 2016 - 9:52am | 258Read More...JetBlue Airways Corporation (NASDAQ: JBLU) guided to a 12.5 percent decline in its April unit revenue, significantly below expectations. Cowen’s Helane Becker upgraded the rating on the company from Market Perform to Outperform, with a price target of $24. Reasons To Buy JetBlue Becker...
-
Netflix Will Beat U.S. Subscriber Expectations In Second Half, Cowen Predicts
Tuesday, April 5, 2016 - 11:09am | 278Read More...Cowen’s John Blackledge mentioned that the February 2016 survey of 2,500 people in the U.S. increased confidence regarding the 2Q16 and FY16 U.S. paid subscriber estimates for Netflix, Inc. (NASDAQ: NFLX), despite an impending price hike. The analyst maintained an Outperform rating on the...
-
Cowen Met With McDonald's Management: Here's What Happened
Monday, March 28, 2016 - 10:12am | 343Read More...Cowen’s Andrew M. Charles maintained a Market Perform rating on McDonald's Corporation (NYSE: MCD), while raising the price target from $116 to $125. Sustaining The Momentum Following investor meetings with Senior Director of Investor Relations Jen Hiser, Charles mentioned that the...
-
Is Republic Airways' Bankruptcy Weighing On Embraer?
Friday, March 4, 2016 - 10:43am | 269Read More...Cowen's Cai von Rumohr downgraded the rating on Embraer SA (ADR) (NYSE: ERJ) from Outperform to Market Perform, while lowering the price target from $39 to $29. "While 2016 delivery/revenue prospects are mostly intact, RJ margins are under pressure despite the likely FX tailwind,...
-
Habit Restaurants Gets Another Vote Of Confidence
Wednesday, March 2, 2016 - 10:59am | 274Read More...Cowen's Andrew M. Charles upgraded the rating on Habit Restaurants Inc (NASDAQ: HABT) from Market Perform to Outperform, while raising the price target from $28 to $30. "An 11 percent YTD pullback in HABT shares on fears of the impact to sales from a promotional QSR environment and a potential...
-
LogMeIn's LastPass Acquisition Gives Investors More Gains
Monday, February 22, 2016 - 11:30am | 265Read More...Cowen's Gregg Moskowitz maintained an Outperform rating on LogMeIn Inc (NASDAQ: LOGM), while raising the price target from $53 to $56. Although the stock is likely to remain rangebound in the near term, Moskowitz continues to believe that there could be more opportunities to monetize for...
-
Cowen Downgrades Pandora Amid 'Lower Ad Loads'
Wednesday, February 10, 2016 - 10:32am | 370Read More...The share price of Pandora Media Inc (NYSE: P) has declined 55.6 percent over the past six months, dropping to less than 20 cents above the 52-week low on February 9. Cowen’s John Blackledge has downgraded the rating on the company from Outperform to Market Perform, while lowering the...
-
La Jolla Pharma Could Nearly Triple, Cowen Says
Tuesday, February 9, 2016 - 11:54am | 260Read More...On Tuesday, Cowen and Company issued a company note on La Jolla Pharmaceutical Company (NASDAQ: LJPC) ahead of multiple drug trials for the company's pipeline. Currently, analysts at Cowen rate La Jolla Pharmaceutical as an Outperform with a $40 price target. Phil Nadeau and Cristina...
-
Cowen Upgrades ADTRAN, Sees Revenue Boost In Future From AT&T Deal
Thursday, February 4, 2016 - 12:20pm | 252Read More...Cowen and Company on Thursday issued a note on ADTRAN, Inc. (NASDAQ: ADTN) after the company won a major deal for the G Fast project with AT&T Inc. (NYSE: T). Cowen upgraded ADTRAN from Under-Perform to Market Perform and raised their price target from $14 to $16. Analysts at Cowen and...
-
American Airlines Inflection Point Is On Its Way, Says Cowen Analyst Amid Upgrade
Monday, February 1, 2016 - 10:49am | 325Read More...Shares of American Airlines Group Inc (NASDAQ: AAL) have declined 20.56 percent over the past one year to a low of $38.14 on January 28. Cowen’s Helane Becker has upgraded the rating on the company from Market Perform to Outperform, while raising the price target from $47 to $48....
-
Pandemic Fears Could Be Major Catalyst For Cerus Drug, Cowen Says
Friday, January 29, 2016 - 11:55am | 266Read More...The share price of Cerus Corporation (NASDAQ: CERS) has declined 16.43 percent over the past month, to a low of $5.01 on Thursday. Cowen’s Joshua Jennings has maintained an Outperform rating on the company, with a price target of $8. An article in Transfusion has highlighted the...
-
Facebook Absolutely Crushed Earnings And The Street Is Loving It
Thursday, January 28, 2016 - 4:02pm | 342Read More...Facebook Inc (NASDAQ: FB) stock is up more than 15 percent on Thursday following a big earnings beat. The social media giant reported fourth quarter earnings of $0.79 per share versus estimates of $0.68, and revenue of $5.84 billion versus estimates of $5.37 billion. Here’s what Wall...
